A single-center, open-label study assessing the change in psychosocial and occupational well-being before and after treatment with ustekinumab in patients with moderate to severe psoriasis - 09/05/15
Argentina Leon, MD, University of California, San Francisco, San Francisco, CA, United States; Kourosh Beroukhim, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States; Catherine Nguyen, University of California, Irvine, School of Medicine, Irvine, CA, United States; Eric Sorenson, University of Southern California, School of Medicine, Los Angeles, CA, United States; Melissa Danesh, University of California, San Francisco, School of Medicine, San Francisco, CA, United States; Gabrielle Brown, MS, University of Arizona College of Medicine, Tuscon, Arizona, United States; Mona Malakouti, MS, Rosalind Franklin University of Medicine, Vernon Hills, IL, United States; Monica Huynh, Chicago College of Osteopathic Medicine, Chicago, IL, United States; Ethan Levin, MD, University of California, San Francisco, San Francisco, CA, United States; Rishu Gupta, MD, University of Southern California, School of Medicine, Los Angeles, CA, United States; John Koo, MD, University of California, San Francisco, School of Medicine, San Francisco, CA, United States
Le texte complet de cet article est disponible en PDF. Supported by Janssen Pharmaceuticals, Inc. |
Vol 72 - N° 5S1
P. AB223 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?